PharmaTher has announced positive topline results from the dose-finding and tolerability clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. The results are adequate to give an effect size in powering a Phase III clinical study, which is expected to bridge the design with increased treatment duration relative to the company’s Phase II clinical study (NCT04912115).
Category Press Release
Published in BioSpace
Companies Featured
PharmaTherPharmather is a Canadian life sciences listed company that is developing psychedelics for brain and nervous system disorders.
Trials Linked
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced DyskinesiaA Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.